CD209 and neoplasm: We designated this myeloid subpopulation “enriched-in-renal-carcinoma DCs” (ercDCs), due to its strong enrichment in the tumor center, where they represent over 60% of the CD209+ population (mean, 62%; range, 26% to 80%), compared to non-tumor kidney cortex (mean, 19%; range, 0% to 43%).